NextCure (NASDAQ:NXTC - Get Free Report) has been assigned a $15.00 target price by equities researchers at Piper Sandler in a research report issued to clients and investors on Tuesday, July 15th, Marketbeat reports. The brokerage currently has an "overweight" rating on the stock. Piper Sandler's target price would indicate a potential upside of 202.11% from the stock's current price.
NXTC has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of NextCure in a report on Tuesday, July 1st. LADENBURG THALM/SH SH raised shares of NextCure to a "hold" rating in a research note on Tuesday, July 8th.
Get Our Latest Stock Report on NXTC
NextCure Price Performance
NASDAQ:NXTC opened at $4.97 on Tuesday. NextCure has a 1-year low of $2.69 and a 1-year high of $20.76. The company has a 50-day moving average of $5.64 and a 200 day moving average of $6.59. The firm has a market cap of $13.31 million, a PE ratio of -0.23 and a beta of 1.06.
NextCure (NASDAQ:NXTC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($4.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.80) by $0.12. Sell-side analysts anticipate that NextCure will post -1.87 EPS for the current fiscal year.
Hedge Funds Weigh In On NextCure
Several institutional investors and hedge funds have recently modified their holdings of NXTC. Citadel Advisors LLC increased its position in shares of NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company's stock worth $61,000 after purchasing an additional 22,724 shares during the period. Renaissance Technologies LLC lifted its holdings in NextCure by 27.9% during the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company's stock worth $400,000 after purchasing an additional 113,300 shares in the last quarter. Tang Capital Management LLC increased its position in shares of NextCure by 7.3% during the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company's stock valued at $540,000 after purchasing an additional 47,614 shares during the last quarter. Finally, Pfizer Inc grew its position in shares of NextCure by 29.7% in the 1st quarter. Pfizer Inc now owns 1,891,763 shares of the company's stock worth $909,000 after buying an additional 433,213 shares during the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.
About NextCure
(
Get Free Report)
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Further Reading
Before you consider NextCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NextCure wasn't on the list.
While NextCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
